Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:28:08 2024-03-28 pm EDT 5-day change 1st Jan Change
419.1 USD +0.42% Intraday chart for Vertex Pharmaceuticals Incorporated +0.94% +3.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vertex Pharmaceuticals Gets FDA Approval for VX-407's Investigational New Drug Application to Treat Kidney Disease MT
Vertex Gets FDA OK to Study VX-407 in Genetic Kidney Disease DJ
Vertex Pharmaceuticals Incorporated Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease CI
Transcript : Vertex Pharmaceuticals Incorporated Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 04:00 PM
Transcript : Vertex Pharmaceuticals Incorporated Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM
Vertex Pharmaceuticals Insider Sold Shares Worth $2,142,974, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $506,546, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,519,637, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Gets Positive Opinion for Kalydeco From European Medicines Agency to Treat Cystic Fibrosis MT
Vertex Pharmaceuticals Cystic Fibrosis Drug Gets Positive Opinion in EU For Treatment in Infants DJ
Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older CI
Prices for new US drugs rose 35% in 2023, more than the previous year RE
RBC Trims Price Target on Vertex Pharmaceuticals to $417 From $420, Keeps Sector Perform Rating MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,776,528, According to a Recent SEC Filing MT
Wolfe Research Initiates Vertex Pharmaceuticals With Outperform Rating, $515 Price Target MT
(OFFICIAL)-Latigo Biotherapeutics raises $135 mln for non-opioid painkillers RE
Vertex Pharmaceuticals Insider Sold Shares Worth $727,822, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,804,931, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $383,679, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,321,655, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $577,410, According to a Recent SEC Filing MT
European Commission Grants Crispr Therapeutics Conditional Marketing Permit for Casgevy MT
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY? (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia CI
Fed officials fail to convince investors, who are focused on earnings Our Logo
North American Morning Briefing : Stock Futures -2- DJ
Chart Vertex Pharmaceuticals Incorporated
More charts
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
417.3 USD
Average target price
459.7 USD
Spread / Average Target
+10.16%
Consensus
  1. Stock
  2. Equities
  3. Stock Vertex Pharmaceuticals Incorporated - Nasdaq
  4. News Vertex Pharmaceuticals Incorporated
  5. Vertex Pharmaceuticals : Morgan Stanley Downgrades Vertex Pharmaceuticals to Underweight from Equalweight, Keeps $202 Price Target